HC Wainwright Estimates Immunome’s Q3 Earnings (NASDAQ:IMNM)

Immunome, Inc. (NASDAQ:IMNM) – HC Wainwright reduced their Q3 2026 earnings estimates for shares of Immunome in a research report issued to clients and investors on Wednesday, August 12th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($0.65) for the quarter, down from their previous forecast of ($0.51). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Immunome’s current full-year earnings is ($2.06) per share. HC Wainwright also issued estimates for Immunome’s Q4 2026 earnings at ($0.68) EPS, FY2026 earnings at ($2.45) EPS, FY2027 earnings at ($2.11) EPS, FY2028 earnings at ($0.85) EPS, FY2029 earnings at $0.40 EPS and FY2030 earnings at $1.08 EPS.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.14).

Several other research analysts also recently commented on the company. Truist Financial raised their price objective on Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a research note on Wednesday. Wedbush raised their target price on shares of Immunome from $31.00 to $35.00 and gave the stock an “outperform” rating in a research note on Wednesday. Barclays assumed coverage on shares of Immunome in a report on Thursday, May 28th. They set an “overweight” rating and a $36.00 price target on the stock. Citigroup reissued a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Finally, Leerink Partners lowered their target price on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a research note on Friday, May 15th. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $34.64.

Immunome Stock Performance

NASDAQ IMNM opened at $26.42 on Friday. The business’s fifty day moving average is $22.02 and its 200 day moving average is $22.20. Immunome has a fifty-two week low of $8.66 and a fifty-two week high of $28.62. The company has a market capitalization of $3.00 billion, a PE ratio of -10.44 and a beta of 2.08.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in IMNM. Allworth Financial LP purchased a new position in Immunome in the second quarter worth about $25,000. KBC Group NV bought a new stake in shares of Immunome in the 1st quarter valued at approximately $60,000. Strs Ohio purchased a new position in shares of Immunome in the 4th quarter worth approximately $64,000. Assetmark Inc. boosted its holdings in shares of Immunome by 46.6% in the 1st quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock worth $99,000 after purchasing an additional 1,442 shares during the period. Finally, State of Wyoming bought a new position in shares of Immunome during the 2nd quarter valued at approximately $109,000. Institutional investors own 44.58% of the company’s stock.

Insider Activity at Immunome

In related news, Director Isaac Barchas sold 101,050 shares of the company’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $21.12, for a total transaction of $2,134,176.00. Following the sale, the director owned 308,504 shares of the company’s stock, valued at $6,515,604.48. This represents a 24.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Max Rosett sold 60,000 shares of Immunome stock in a transaction on Monday, June 15th. The stock was sold at an average price of $18.23, for a total transaction of $1,093,800.00. Following the completion of the transaction, the chief financial officer directly owned 54,037 shares of the company’s stock, valued at $985,094.51. The trade was a 52.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 682,310 shares of company stock worth $15,675,566 over the last 90 days. Company insiders own 7.21% of the company’s stock.

Immunome News Roundup

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: Analyst support and potential catalysts remain significant. Truist raised its price target to $38 from $37 and reiterated a Buy rating. Separately, Immunome’s varegacestat NDA has been accepted by the FDA, with a PDUFA decision expected in April 2027. The company also expects initial 2026 data from its Phase 1 IM-1021 ROR1 antibody-drug conjugate program. Truist price target update Immunome clinical catalysts analysis
• Positive Sentiment: Institutional ownership provides a supportive backdrop. BlackRock established an approximately $186.6 million position, while T. Rowe Price and Primecap increased their holdings. Institutional investors collectively own about 44.6% of Immunome’s shares, indicating substantial professional-investor interest in the pipeline.
• Neutral Sentiment: Director selling adds a supply concern but was conducted under a Rule 10b5-1 plan. Director Isaac Barchas sold roughly 98,700 shares from August 10–12 for approximately $2.6 million, reducing his direct holdings to 92,211 shares. The pre-arranged nature of the transactions makes them a less definitive signal about his current outlook. Immunome director SEC filing
• Negative Sentiment: Earnings and estimates are weighing on sentiment. Immunome reported a second-quarter loss of $0.65 per share, wider than the $0.51 consensus estimate. HC Wainwright subsequently reduced its Q3 2026 estimate to a $0.65 loss from $0.51, cut Q4 to a $0.68 loss from $0.53, and lowered full-year 2026 and 2027 estimates to losses of $2.45 and $2.11 per share, respectively. The report triggered a gap lower after earnings, despite HC Wainwright maintaining its Buy rating. Immunome second-quarter results Immunome shares gap down after earnings miss

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.